Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지
DOI QR코드

DOI QR Code

Salivary Gland Carcinoma Mimicking Secretory Breast Cancer

분비성 유방암과 유사한 침샘 암종

  • Song, Chang Myeon (Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Hanyang University) ;
  • Min, Jung Seon (Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Hanyang University) ;
  • Shin, Su-Jin (Department of Pathology, College of Medicine, Hanyang University) ;
  • Tae, Kyung (Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Hanyang University)
  • 송창면 (한양대학교 의과대학 이비인후-두경부외과학교실) ;
  • 정선민 (한양대학교 의과대학 이비인후-두경부외과학교실) ;
  • 신수진 (한양대학교 의과대학 병리학교실) ;
  • 태경 (한양대학교 의과대학 이비인후-두경부외과학교실)
  • Received : 2017.10.31
  • Accepted : 2017.11.08
  • Published : 2017.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Mammary analogue secretory carcinoma (MASC) of the salivary gland is a newly classified pathologic entity since 2010. Prior to its recognition, MASC was diagnosed as low-grade cystadenocarcinoma, acinic cell carcinoma, and mucoepidermoid carcinoma. MASC shares common histological and genetic characteristics with secretory carcinoma of the breast and has a distinct feature of the ETV6-NTRK3 fusion gene. Treatment of MASC in salivary gland is mainly wide surgical resection of the tumor. Prognosis of MASC is similar to other low-grade salivary gland carcinomas. Herein, we report a case of MASC developed in a parotid gland with a review of the literature.

Keywords

References

  1. Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599-608.
  2. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367-376. https://doi.org/10.1016/S1535-6108(02)00180-0
  3. Sethi R, Kozin E, Remenschneider A, Meier J, VanderLaan P, Faquin W, et al. Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy. Laryngoscope. 2014;124:188-195. https://doi.org/10.1002/lary.24254
  4. Suzuki K, Yagi M, Kanda A, Kobayashi Y, Konishi M, Miyasaka C, et al. Mammary Analogue Secretory Carcinoma Presenting as a Cervical Lymph Node Metastasis of Unknown Primary Site: A Case Report. Case Rep Oncol. 2017;10:192-198. https://doi.org/10.1159/000457949
  5. Dettloff J, Seethala RR, Stevens TM, Brandwein-Gensler M, Centeno BA, Otto K, et al. Mammary Analog Secretory Carcinoma (MASC) Involving the Thyroid Gland: A Report of the First 3 Cases. Head Neck Pathol. 2017;11:124-130. https://doi.org/10.1007/s12105-016-0741-6
  6. Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013;7:35-39. https://doi.org/10.1007/s12105-013-0429-0
  7. Ni H, Zhang XP, Wang XT, Xia QY, Lv JH, Wang X, et al. Extended immunologic and genetic lineage of mammary analogue secretory carcinoma of salivary glands. Hum Pathol. 2016;58:97-104. https://doi.org/10.1016/j.humpath.2016.09.001
  8. Levine P, Fried K, Krevitt LD, Wang B, Wenig BM. Aspiration biopsy of mammary analogue secretory carcinoma of accessory parotid gland: another diagnostic dilemma in matrix-containing tumors of the salivary glands. Diagn Cytopathol. 2014;42:49-53. https://doi.org/10.1002/dc.22886
  9. Ito S, Ishida E, Skalova A, Matsuura K, Kumamoto H, Sato I. Case report of Mammary Analog Secretory Carcinoma of the parotid gland. Pathol Int. 2012;62:149-152. https://doi.org/10.1111/j.1440-1827.2011.02759.x
  10. Din NU, Fatima S, Kayani N. Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic study of 11 cases. Ann Diagn Pathol. 2016;22:49-53. https://doi.org/10.1016/j.anndiagpath.2016.04.003
  11. Connor A, Perez-Ordonez B, Shago M, Skalova A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012;36:27-34. https://doi.org/10.1097/PAS.0b013e318231542a
  12. Skalova A. Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol. 2013;7 Suppl 1:S30-36. https://doi.org/10.1007/s12105-013-0455-y
  13. Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005;61:103-111. https://doi.org/10.1016/j.ijrobp.2004.03.018
  14. Baghai F, Yazdani F, Etebarian A, Garajei A, Skalova A. Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin. Pathol Res Pract. 2017;213:1112-1118. https://doi.org/10.1016/j.prp.2017.07.017
  15. Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27:920-926. https://doi.org/10.1093/annonc/mdw042

Cited by

  1. A Case of Mammary Analogue Secretory Carcinoma of the Parotid Gland vol.29, pp.2, 2017, https://doi.org/10.35420/jcohns.2018.29.2.290